Wire · opportunities
Neuren secures European approval for Rett syndrome treatment
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 25 August 2026 · Fusion42 review
Neuren Pharmaceuticals received European Commission approval for DAYBU (trofinetide) to treat neurobehavioural symptoms of Rett syndrome, marking the first authorised treatment for this condition in the EU and related countries. This approval opens a significant commercial pathway for Neuren under its licensing deal with Acadia Pharmaceuticals, with reimbursable sales expected to start in Germany in late 2026.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You now have the first approved option to treat Rett syndrome symptoms in Europe, turning clinical hope into a market reality and financial incentives for Neuren and Acadia. Prepare to engage with European payers and families early ahead of Daybu's 2026 rollout in Germany.
◆ Coverage
1 source · 25 Aug 2026
◆ Related on Wire
◆ Topics